{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T16:39:47Z","timestamp":1775493587828,"version":"3.50.1"},"reference-count":26,"publisher":"Korean Cancer Association","issue":"3","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"name":"Dong-A research fund","award":["2018-31-090"],"award-info":[{"award-number":["2018-31-090"]}]}],"content-domain":{"domain":["e-crt.org"],"crossmark-restriction":true},"short-container-title":["Cancer Res Treat"],"published-print":{"date-parts":[[2024,7,15]]},"abstract":"<jats:p>Purpose The locally advanced unresectable intrahepatic cholangiocarcinoma (ICC) has detrimental oncological outcomes. In this study, we aimed to investigate the efficacy of radiotherapy in patients with locally advanced unresectable ICC.Materials and Methods Between 2001 and 2021, 116 patients were identified through medical record who underwent radiotherapy for locally advanced unresectable ICC. The resectability of ICC is determined by the multidisciplinary team at each institution. Overall survival (OS) were analyzed using the Kaplan-Meier method, and prognostic factors were analyzed using the Cox proportional hazards model.Results The median equivalent radiotherapy dose in 2 Gy fractions (EQD2) was 52 Gy (range, 30 to 110 Gy). Forty-seven patients (40.5%) received sequential gemcitabine-cisplatin based chemotherapy (GEM-CIS CTx). Multivariate analysis identified two risk factors, EQD2 of \u2265 60 Gy and application of sequential GEM-CIS CTx for OS. Patients were grouped by these two risk factors: group 1, EQD2 \u2265 60 Gy with sequential GEM-CIS CTx (n=25); group 2, EQD2 &lt; 60 Gy with sequential GEM-CIS CTx or fluoropyrimidine-based concurrent chemoradiotherapy (n=70); and group 3, radiotherapy alone (n=21). Curative resection was more frequently undergone in group 1 than in groups 2 or 3 (28% vs. 8.6% vs. 0%, respectively). Consequently, OS was significantly better in group 1 than in groups 2 and 3 (p &lt; 0.05).Conclusion Combined high-dose radiotherapy with sequential GEM-CIS CTx improved oncologic outcomes in patients with locally advanced unresectable ICC. Further prospective studies are required to validate these findings.<\/jats:p>","DOI":"10.4143\/crt.2023.886","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T01:36:16Z","timestamp":1704245776000},"page":"838-846","update-policy":"https:\/\/doi.org\/10.4143\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Combined High-Dose Radiotherapy with Sequential Gemcitabine-Cisplatin Based Chemotherapy Increase the Resectability and Survival in Locally Advanced Unresectable Intrahepatic Cholangiocarcinoma: A Multi-institutional Cohort Study"],"prefix":"10.4143","volume":"56","author":[{"given":"Jung Ho","family":"Im","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong Il","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Gyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinsil","family":"Seong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2954","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010676"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0908721"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605779"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt540"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.4_suppl.378"},{"key":"ref6","first-page":"1853","volume-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","author":"Kelley","year":"2023"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz071"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30488"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.61.3778"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.64.2710"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34223"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-08142-9"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2021.09.004"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2018.09.010"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/ppo.0000000000000213"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717x-8-292"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2018.01.15"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.01.021"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2017.03.001"},{"key":"ref20","first-page":"871","volume-title":"A simple alpha\/beta-independent method to derive fully isoeffective schedules following changes in dose per fraction","author":"Joiner","year":"2004"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1247132"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.11154"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2018.11.015"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2019.08.003"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12843"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.4_suppl.lba490"}],"container-title":["Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2023-886.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2023.886","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2023-886.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T01:37:54Z","timestamp":1721007474000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2023.886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"URL":"https:\/\/doi.org\/10.4143\/crt.2023.886","relation":{},"ISSN":["1598-2998","2005-9256"],"issn-type":[{"value":"1598-2998","type":"print"},{"value":"2005-9256","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,15]]},"assertion":[{"value":"2023-07-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-02","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-15","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}